-

Meilleur Technologies Inc. Announces Execution of Manufacturing Agreement with PharmaLogic for Production of the Next-Generation Amyloid PET Imaging Biomarker, NAV4694

Knoxville, TN and Boca Raton, FL--(BUSINESS WIRE)--Meilleur Technologies Inc. (MTI) today announced it has signed an agreement with PharmaLogic Holdings Corporation (“PharmaLogic”) granting PharmaLogic the rights to manufacture fluorine-18 [F18]NAV4694, a next-generation investigational imaging biomarker used in Positron Emission Tomography (PET) imaging studies to assess the status of amyloid plaque in the brain. Amyloid plaques are one of the pathological hallmarks of several neurodegenerative diseases, including Alzheimer’s Disease (AD).

Under the terms of its agreement, PharmaLogic will manufacture [F18]NAV4694 for use in clinical trials at select United States-based radiopharmacies.

“We are delighted that the NAV4694 clinical and research program will be supported by Pharmalogic's extensive PET manufacturing and dispensing expertise,” said Rick Hiatt, President and CEO of Meilleur Technologies, Inc. “Meilleur is focused on enabling acceleration of technologies that have the potential to advance the fight against debilitating neurodegenerative disease. Additionally, we believe NAV4694 has unique properties that will prove useful in developing current and future therapeutic agents in neurodegenerative disease and are excited to add PharmaLogic to our growing network of pharmaceutical and academic partners. Our goal is to expand the availability of this novel investigational imaging agent to the broader scientific community.”

“PharmaLogic is pleased to partner with Meilleur Technologies furthering our commitment to help combat some of the world's most challenging diseases, including Alzheimer's Disease,” said Steve Chilinski, CEO of PharmaLogic.

About Meilleur Technologies, Inc.

Meilleur’s vision is to be the premier provider of imaging biomarkers for neurological pathologies, associated information technology and related tools to accelerate the development, approval, and adoption of effective therapies to treat neurodegenerative diseases. Meilleur’s late-stage biomarker, NAV-4694, provides Pharma and Academic researchers with a ‘best in class’ second generation ß-Amyloid imaging biomarker capable of detecting and validating Disease Modifying Therapies with the highest possible precision and accuracy for determining the risk of Alzheimer’s disease.

About PharmaLogic

PharmaLogic is a world-class North American contract development and manufacturing organization specializing in novel diagnostic imaging and therapeutic radiopharmaceuticals for the treatment of cancers and other diseases. In addition to an established and reliable network of radiopharmacies, PharmaLogic has decades of expertise in drug development from discovery, through manufacturing and commercialization. The Company seeks to take the lead in the advancement of radiopharmaceutical technology for the benefit of patients worldwide. For more information, visit: www.radiopharmacy.com

Contacts

Meilleur Technologies, Inc.
Rick Hiatt, +1 617-906-2715

PharmaLogic Holdings Corporation
Taylor Prejna, +1 571 595 8258

Industry:

Meilleur Technologies, Inc.

Release Versions
English

Contacts

Meilleur Technologies, Inc.
Rick Hiatt, +1 617-906-2715

PharmaLogic Holdings Corporation
Taylor Prejna, +1 571 595 8258

More News From Meilleur Technologies, Inc.

Enigma Biomedical USA awarded a grant from The Michael J. Fox Foundation for Discovery and Development of Novel α-Synuclein PET Imaging Biomarker

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Enigma Biomedical USA (EB USA) today announced that The Michael J. Fox Foundation for Parkinson’s Research (MJFF), has awarded EB USA $2 million for the discovery and initial preclinical development of a novel α-synuclein Positron Emission Tomography (PET) Imaging biomarker. This funding is part of MJFF’s strategic research agenda focused on supporting objective tools to biologically measure and track the progression of Parkinson’s disease (PD) to improve clin...

Enigma Biomedical USA announces FDA Acceptance of New Drug Application for florquinitau F-18 (MK-6240), a Tau PET Alzheimer’s Disease radiodiagnostic

KNOXVILLE, Tenn. & BEDFORD, Mass.--(BUSINESS WIRE)--Enigma Biomedical USA (EB USA) today announced that the Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for MK-6240 (florquinitau F-18), their Tau Positron Emission Tomography (PET) Alzheimer’s disease radiodiaganostic. The FDA previously granted MK-6240 fast track status, which is a recognition of the potential to address an important unmet need. MK-6240 specifically targets a pathological form of tau called tau n...

Enigma Biomedical USA, Inc. Announces a Collaboration to Apply Novel 4R PET Imaging Biomarkers to CTE Research

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Enigma Biomedical USA, Inc. (EB USA) today announced that it is starting a collaboration with the Boston University Chronic Traumatic Encephalopathy (CTE) Center and the Concussion Legacy Foundation. This collaboration will focus on demonstrating the value of 4R Tau PET imaging biomarkers in advancing our understanding of CTE. The initial aspects of the CTE partnership will involve autoradiographic and immunohistochemical assessment of the binding of high affi...
Back to Newsroom